SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently a focal point for investors as intense debate rages between bulls encouraged by a high-profile presidential endorsement and bears like Michael Burry who argue the stock remains significantly overvalued. The community is actively weighing the company's long-term utility in government and defense sectors against ongoing concerns regarding market volatility, technical trendline resistance, and the potential impact of competing AI platforms.

Maulcoin

Maulcoin is trending as its community of 'Maulers' aggressively promotes a 'diamond hands' hold strategy to drive the asset toward higher market cap milestones. Investors are actively discussing organic growth, potential airdrops for verified holders, and the goal of achieving mainstream visibility as they push for a chart listing on tracking platforms.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is undergoing a volatile surge as institutional interest intensifies ahead of its upcoming inclusion in the Nasdaq-100, fueling intense debate between retail bulls betting on a stock split or short squeeze and skeptical bears citing unsustainable valuations compared to historical norms. While proponents highlight SanDisk's dominant role in AI data center storage and multi-year supply agreements, critics argue the stock is displaying classic bubble behavior and overextension, leading to significant discord over the stock's future trajectory following such a parabolic run.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heavy market volatility as investors weigh the stock's role as a leveraged Bitcoin proxy against ongoing share dilution and macro-driven price swings. The community is actively debating whether current price action represents a strategic accumulation zone ahead of potential institutional catalysts or a structural vulnerability to continued dilution and BTC correlation risks.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors aggressively debate the stock's future, balancing concerns over competitive pressure from emerging AI agents against the company's strong fundamentals, including a robust cash position and zero debt. The community is heavily divided, with many retail investors viewing the recent volatility as a classic short squeeze setup while others express frustration over the sustained downward price trend despite the company's profitability.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is trending as the community highlights its unique blend of memecoin culture and real-world business integration through their 'Cocky Wings' food truck operations. Investors are actively discussing the project's passive income opportunities and revenue-fueled buyback programs, framing it as a community-driven project with sustained long-term growth potential.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently capturing significant investor attention as the community debates its potential to disrupt the photonics sector through its proprietary electro-optic polymer technology. Fueled by recent foundry integration news and speculation regarding high-profile partnerships, the stock is experiencing high volatility as traders weigh long-term growth prospects against concerns over pre-revenue status and short-term market speculation.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are actively debating the merits of high-yield ETFs like QQQI, with community sentiment split between concerns over NAV erosion and excitement over the potential for consistent monthly income. Many participants are focused on using these distributions to strategically accumulate more shares, viewing the fund as a tax-efficient cornerstone for long-term passive income generation despite broader market volatility.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is seeing heightened investor attention as market participants debate its long-term potential in the AI-driven data and marketing sector versus the ongoing volatility impacting SaaS stocks. While some investors are aggressively loading shares on recent dips, citing strong revenue growth and improving free cash flow, others are expressing frustration over stagnant price action and technical pressure from short sellers.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow ($NOW) is currently trending as investors debate whether the stock is experiencing a fundamental structural decline due to AI-driven disruption or a deep value opportunity following a sharp selloff. The community is heavily focused on the stock's recent valuation compression and potential mispricing, with many active traders and long-term holders debating the impact of AI agent integration versus the risk of platform replacement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>ImmunityBio said it removed the referenced podcast from its website and requested removal from external platforms.</li><li>Enhanced compliance measures will include stricter promotional review protocols and mandatory executive-level training.</li><li>ANKTIVA, ImmunityBio’s interleukin-15-based immunotherapy, remains central to the company’s oncology strategy.</li></ul>ImmunityBio Inc. (IBRX) stated on Monday that it has responded to regulatory concerns raised by the U.S. Food and Drug Administration, outlining corrective steps related to promotional content for its cancer therapy as the company seeks to reinforce compliance standards.The company said it submitted a detailed reply to the FDA’s Office of Prescription Drug Promotion following a March 13 communication on marketing materials, including a podcast and a television advertisement.&nbsp;<h2 class="st-heading-2">FDA Inquiry And ImmunityBio’s Response</h2>ImmunityBio clarified that the advertisement in question was never released to the public and addressed issues tied to statements made in the podcast.&nbsp;In response, ImmunityBio removed the referenced podcast from its website and requested its deletion from external platforms hosting the content.&nbsp;<blockquote>“We are dedicated to maintaining a clear distinction between our investigational pipeline aspirations and the promoted indications for our approved therapies.”-Richard Adcock, President and CEO, ImmunityBio</blockquote>&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio stock</a> traded over 3% higher in Monday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;<h2 class="st-heading-2">Strengthening Compliance Measures</h2>The Culver City-based firm said it is introducing tighter oversight procedures, including enhanced review protocols for marketing materials, mandatory executive-level compliance training, and the addition of external regulatory advisors to evaluate future communications. These measures are intended to ensure that promotional messaging aligns with FDA standards for accuracy and balance.The podcast in question featured founder Patrick Soon-Shiong, who was discussing long-term scientific ambitions.The company emphasized its commitment to providing clear and compliant information about ANKTIVA, an immunotherapy designed to stimulate key immune cells that target cancer. The treatment builds on the biology of interleukin-15 to enhance the immune response, forming part of ImmunityBio’s broader oncology strategy.IBRX stock has gained over 268% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slno-stock-soars-over-39-what-s-fueling-the-rally/cZJ4SjzRIoU">SLNO Stock Soars Over 39% — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight

ImmunityBio company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.

Equity

The company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.


<ul class="summary-bullets"><li>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments.</li><li>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030.</li><li>In February, Day One reported strong momentum for its lead therapy, OJEMDA.</li></ul>Day One Biopharmaceuticals, Inc. (DAWN) announced on Friday that it has entered into an acquisition agreement with Servier, an independent pharmaceutical company managed by a foundation.The deal, valued at roughly $2.5 billion, will see Servier purchase Day One shares for $21.50 each in cash, marking a 64% premium over DAWN’s closing price on Thursday.<h2 class="st-heading-2">Expansion In Oncology</h2>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments and broaden its cancer pipeline for both adults and children facing high unmet medical needs.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/DAWN">Day One Biopharmaceuticals stock</a> surged over 65% on Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.<h2 class="st-heading-2">Pipeline Growth And 2030 Ambition</h2>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030. The addition of Day One’s programs, ranging from early-stage research to phase 3 trials, enhances Servier’s capacity to deliver solutions for cancers with critical unmet needs.<blockquote>“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma.”-Jeremy Bender, CEO, Day One</blockquote>In February, Day One&nbsp;reported strong momentum for its lead therapy, OJEMDA, highlighting prescription volumes for OJEMDA reached 1,394 in the fourth quarter of 2025, with total prescriptions for the year at 4,635, marking a 181% year-on-year (YOY) growth.&nbsp;The company said updated three-year results from the Phase 2 FIREFLY-1 trial demonstrated durable responses and long-term safety of OJEMDA in relapsed or refractory pediatric low-grade glioma (pLGG). Enrollment for the pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in frontline pLGG remains on schedule, with full enrollment expected in the first half of 2026.DAWN stock traded over 132% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-in-spotlight-as-company-strengthens-us-nuclear-fuel-supply-chain-with-new-deal/cZdLbbRRIEr">ASPI Stock In Spotlight As Company Strengthens US Nuclear Fuel Supply Chain With New Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Day One Biopharmaceuticals logo is displayed on the screen of a tablet.

Why Did DAWN Skyrocket Over 65% Pre-Market Today? 

Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.

<ul class="summary-bullets"><li>The company reported Q4 revenue of $92.02 million with an earnings per share (EPS) of $0.15.</li><li>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions.</li><li>The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.</li></ul>Liquidia Corp. (LQDA) on Thursday released its financial results for the fourth quarter (Q4), highlighting strong early traction in the commercial rollout of its respiratory drug, YUTREPIA.&nbsp;The company reported Q4 revenue of $92.02 million&nbsp;with an earnings per share (EPS) of $0.15. While revenue surpassed the analysts’ consensus estimate of $83.70 million, EPS came in below the $0.19 estimate, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">YUTREPIA Launch Drives Commercial Momentum</h2>The North Carolina-based company reported significant prescription growth for YUTREPIA since its U.S. launch in June 2025, with thousands of patients now receiving therapy. The drug’s early performance has become a key contributor to Liquidia’s improving financial outlook and operational momentum.Product revenue from YUTREPIA reached approximately $148.3 million in 2025,&nbsp;including about $90.1 million generated during the fourth quarter alone.<blockquote>“We believe YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across serious and progressive cardiopulmonary diseases.”-Roger Jeffs, CEO, Liquidia&nbsp;</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/LQDA">Liquidia’s stock</a> traded over 6% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ in 24 hours.&nbsp;<h2 class="st-heading-2">What’s Next?&nbsp;</h2>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions, with over 2,900 patients already starting treatment. The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.Jeffs said the company plans to increase the number of doctors prescribing the treatment, expand the sales team, add more clinical data for YUTREPIA through several new studies, and move L606 into key late-stage trials, all using funds generated from business operations.LQDA stock has gained over 121% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meta-lacks-deep-pool-of-cloud-demand-unlike-google-and-amazon-says-arete/cZdQYbhRI3T">Meta Lacks The 'Deep Pool' Of Cloud Demand, Unlike Google And Amazon, Says Arete</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Liquidia Corporation logo is seen displayed on a smartphone screen.

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth 

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

<ul class="summary-bullets"><li>The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.</li><li>Interim analysis of the Phase 2 trial showed 84% of patients on the combo maintained a complete response, compared to 52% on BCG alone at nine months.</li><li>ImmunityBio’s 431% revenue growth in Q4 was largely driven by ANKTIVA sales, the company said.</li></ul>Shares of ImmunityBio (IBRX) reversed pre-market gains to trade 3% lower on Thursday&nbsp;after the company completed enrollment ahead of schedule in its Phase 2 ANKTIVA trial and reported that an FDA-requested interim analysis showed significantly longer complete responses with no major safety concerns.The Phase 2 trial studied ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve non-muscle invasive bladder cancer. The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.The company plans to submit a biologics license application by the fourth quarter of 2026.&nbsp;Last week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">granted</a> conditional marketing approval for Anktiva to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.<h2 class="st-heading-2">ANKTIVA-BCG Combo Significantly Improves Complete Response Duration</h2>An interim analysis requested by the U.S. Food and Drug Administration (FDA) showed that the combination significantly improved the duration of complete response, with no major safety concerns. At nine months, 84% of patients on the combo maintained a complete response, compared with 52% on BCG alone.“We are encouraged by these interim results and await the final unblinding of the completed trial. If approved, ANKTIVA plus BCG could offer a new treatment option earlier in the disease course for patients with NMIBC CIS, building on the therapy’s existing approval in the BCG-unresponsive setting,” said Patrick Soon-Shiong, Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.ANKTIVA continues to power ImmunityBio’s growth, with fourth-quarter net product revenue soaring 431% to $38.3 million, beating Wall Street expectations on strong sales of the drug.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on for <a href="https://stocktwits.com/symbol/IBRX/sentiment">IBRX</a> Stocktwits has remained ‘extremely bullish’ zone for the past six months, while message volumes have been ‘extremely high’.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_b893b9958b.webp" alt="IBRX.jpg">One user said the trial’s outcome is strong enough to justify considering Anktiva + BCG as the “standard of care in BCG-naive NMIBC.”<stembedurl>https://stocktwits.com/Adi121/message/645956934</stembedurl>Another user expects consolidation before the next leg of the rally.<stembedurl>https://stocktwits.com/Texas12/message/645972831</stembedurl>Year-to-date, the stock has shot up 350%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

BBP
ETFis Series Trust I - Virtus LifeSci Biotech Products ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BBP News

BBPETFis Series Trust I - Virtus LifeSci Biotech Products ETF